See more : Essar Shipping Limited (ESSARSHPNG.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Otonomy, Inc. (OTIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Otonomy, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TIME dotCom Berhad (5031.KL) Income Statement Analysis – Financial Results
- Bravo Multinational Incorporated (BRVO) Income Statement Analysis – Financial Results
- Lam Research Corporation (LRCX) Income Statement Analysis – Financial Results
- Titanium Transportation Group Inc. (TTNM.TO) Income Statement Analysis – Financial Results
- Mobeus Income & Growth 2 VCT Plc (MIG.L) Income Statement Analysis – Financial Results
Otonomy, Inc. (OTIC)
About Otonomy, Inc.
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 125.00K | 273.00K | 600.00K | 745.00K | 1.24M | 683.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 370.00K | 1.19M | 912.00K | 946.00K | 3.10M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -245.00K | -915.00K | -312.00K | -201.00K | -1.86M | -981.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -196.00% | -335.16% | -52.00% | -26.98% | -150.65% | -143.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 34.67M | 28.00M | 32.81M | 31.84M | 42.70M | 60.72M | 38.76M | 31.80M | 16.34M | 8.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.78M | 23.21M | 7.84M | 3.51M | 2.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.71M | 14.58M | 11.69M | 20.01M | 46.84M | 49.78M | 23.21M | 7.84M | 3.51M | 2.41M |
| Other Expenses | 0.00 | -1.24M | 132.00K | 1.69M | 1.27M | 898.00K | 308.00K | -3.24M | -14.00K | 3.71M |
| Operating Expenses | 49.38M | 42.57M | 44.50M | 51.85M | 89.54M | 110.50M | 61.98M | 39.64M | 19.85M | 10.93M |
| Cost & Expenses | 49.75M | 43.76M | 45.41M | 52.80M | 92.64M | 112.16M | 61.98M | 39.64M | 19.85M | 10.93M |
| Interest Income | 43.00K | 326.00K | 1.72M | 1.69M | 1.27M | 899.00K | 419.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.60M | 1.57M | 1.59M | 4.00K | 0.00 | 0.00 | 0.00 | 39.00K | 2.53M | 444.00K |
| Depreciation & Amortization | 856.00K | 1.06M | 1.15M | 1.19M | 1.29M | 708.00K | 358.00K | 213.00K | 257.00K | 192.00K |
| EBITDA | -49.63M | -43.49M | -44.81M | -52.05M | -91.40M | -111.48M | -61.98M | -39.64M | -19.61M | -7.03M |
| EBITDA Ratio | -39,700.00% | -15,929.30% | -7,467.83% | -6,986.98% | -7,394.90% | -16,322.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -49.63M | -43.49M | -44.81M | -52.05M | -91.40M | -111.48M | -61.98M | -39.64M | -19.85M | -10.93M |
| Operating Income Ratio | -39,700.00% | -15,929.30% | -7,467.83% | -6,986.98% | -7,394.90% | -16,322.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.56M | -1.24M | 132.00K | 1.69M | 1.27M | 898.00K | 308.00K | -3.24M | 291.00K | 3.36M |
| Income Before Tax | -51.18M | -44.73M | -44.68M | -50.37M | -90.13M | -110.58M | -61.67M | -42.88M | -19.56M | -7.57M |
| Income Before Tax Ratio | -40,944.80% | -16,384.98% | -7,445.83% | -6,760.81% | -7,292.07% | -16,190.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -856.00K | -1.06M | -1.15M | -1.19M | -1.29M | -708.00K | -358.00K | -213.00K | 2.51M | 4.15M |
| Net Income | -50.33M | -43.67M | -43.53M | -49.18M | -88.84M | -110.58M | -61.67M | -42.88M | -19.56M | -7.57M |
| Net Income Ratio | -40,260.00% | -15,995.97% | -7,254.33% | -6,601.61% | -7,187.78% | -16,190.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.79 | -1.07 | -1.42 | -1.61 | -2.93 | -3.69 | -2.57 | -5.46 | -1.70 | -0.66 |
| EPS Diluted | -0.79 | -1.07 | -1.42 | -1.61 | -2.93 | -3.69 | -2.57 | -5.46 | -1.70 | -0.66 |
| Weighted Avg Shares Out | 63.44M | 40.85M | 30.73M | 30.61M | 30.30M | 29.96M | 23.95M | 7.85M | 11.47M | 11.47M |
| Weighted Avg Shares Out (Dil) | 63.44M | 40.85M | 30.73M | 30.61M | 30.30M | 29.96M | 23.95M | 7.85M | 11.47M | 11.47M |
Otonomy, Inc. (OTIC) CEO David Weber on Q3 2020 Results - Earnings Call Transcript
Otonomy (OTIC) Reports Q3 Loss, Misses Revenue Estimates
Otonomy, Inc. (OTIC) CEO David Weber On Q3 2020 Results - Quick Version Earnings Call Transcript
Otonomy: Q3 Earnings Insights
Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
Stocks To Watch: Big Focus On Big Tech
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
Source: https://incomestatements.info
Category: Stock Reports